Responsive grants enable The Law Foundation of Ontario to fund ideas generated by nonprofit community groups to improve access to justice. Responsive grants aim to encourage new ideas, approaches, and relationships that can help address emerging needs and connect more people to legal information and supports, especially people who are not currently being reached.

The Natural Sciences and Engineering Research Council of Canada (NSERC) is partnering with the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) to fund collaborative research projects on hydrogen and fuel cell technologies. 

This competition aims to fund ten preliminary (one-year) projects. The proposals to NSERC should not exceed CAN$50,000. All project expenditures are subject to the principles and directives governing the appropriate use of grant funds as outlined in the Tri-agency guide on financial administration. You must follow the Tri-agency open access policy, and you are also encouraged to make any publication data resulting from funded projects open access.

The current initiative is designed to fund preliminary (one-year) projects between Canadian academic researchers and their counterparts in German academia and/or federal research institutes. It is expected that these projects will

• provide training opportunities for Canadian students and postdoctoral fellows
• provide opportunities for networking and interchanges between Canadian researchers and their counterparts in Germany
• lay the groundwork for longer term collaborations that will help advance the development and deployment of hydrogen and fuel cell technologies

The FY21 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.

The FY21 LCRP Clinical Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a critical problem or question in lung cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. In addition, one partner in the collaboration is strongly encouraged to be an active duty Service member or Federal employee from a Department of Defense (DoD) military treatment facility or laboratory, or a Department of Veterans Affairs (VA) medical center or research laboratory. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged but not required. At least one member of the partnership must have experience either in lung cancer research or lung cancer patient care. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.

This mechanism is intended to support a pilot, proof-of-principle, or early-phase clinical trial and associated correlative science. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of interventions on biomedical or behavioral health-related outcomes. It is expected that the proposed trial will have a welldeveloped rationale, strong preliminary data, trial methodology, and execution plan. Any proposed preclinical studies in addition to the trial should be appropriately justified as to its necessity to inform and interpret trial results and the correlative science. If the proposed research would ultimately require U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) and/or Investigational Device Exemption (IDE) submission, applications must demonstrate availability of, and access to, clinical reagents (e.g., therapeutic molecules) and patient population(s).

The Chan Zuckerberg Initiative invites applications in support of open source software projects that are essential to biomedical research. The goal of the program is to support software maintenance, growth, development, and community engagement for these critical tools.

The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute have partnered to form the ADDF-Harrington Scholar program. The program recognizes physicians or scientists across the US, Canada and the United Kingdom, who are doing research to develop drugs to prevent, treat and cure Alzheimer’s disease. The award provides funding and drug development support to help bridge the gap between basic discovery and the clinical realm.

Program Description

Up to 3 ADDF-Harrington Scholars are chosen each year. The award includes:

• Funding up to $600,000 over two years
• Drug development expertise and project management support through the Harrington Discovery Institute Therapeutics Development Team
• Consulting services from highly experienced drug development personnel
• Business and commercialization advice
• Clinical development advice
• Regulatory assistance
• Intellectual property review and advice
• Assistance identifying and securing additional financial support based on project needs

The Harrington Discovery Institute and its Therapeutics Development team will work closely with the awardee and their affiliated institution to maximize the clinical and commercial potential of the selected project.

What We Fund

The ADDF-Harrington Scholar Award selection committee seeks breakthrough discovery defined by innovation, creativity and potential clinical impact, including:

• Discoveries deemed to address unmet medical needs
• Modulators of novel targets
• Potential to be developed into a commercial program
• Possess strong intellectual property (IP) or protection strategy
• May be either a small molecule, biologic, or other therapeutic modality
• Diagnostics or devices only acceptable as part of a therapeutic development project or if completely transformative

Eligibility

Scope